ROIX — Response Oncology Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
1997 December 31st | C1998 December 31st | C1999 December 31st | 2000 December 31st | 2001 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K405 | 10-K405 | 10-K405 | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 102 | 128 | 136 | 131 | 118 |
Cost of Revenue | |||||
Gross Profit | 52.8 | 61 | 55.4 | 41.4 | 28.2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 94.6 | 161 | 136 | 152 | 172 |
Operating Profit | 7.37 | -32.4 | -0.829 | -21.1 | -53.7 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 6.78 | -33.2 | -1.53 | -21.7 | -53.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4.2 | -17.4 | -1.69 | -14.4 | -51.4 |
Net Income Before Extraordinary Items | |||||
Net Income | 4.2 | -17.4 | -1.69 | -14.4 | -51.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 4.2 | -17.4 | -1.69 | -14.4 | -51.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.36 | 0.467 | -0.037 | -0.33 | -1.59 |
Dividends per Share |